TECH Bio-Techne Corporation logo

TECH Bio-Techne Corporation

Healthcare
$48.21+1.77%ClosedMarket Cap: $7.55B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

103.84

PEG

P/B

3.60

P/S

6.23

EV/EBITDA

29.45

DCF Value

$22.08

FCF Yield

3.6%

Div Yield

0.7%

Margins & Returns

Gross Margin

65.0%

Operating Margin

12.7%

Net Margin

9.0%

ROE

5.5%

ROA

4.3%

ROIC

4.7%

Financials

View All
PeriodRevenueNet IncomeEPS
Q3 null$311.4M$51.1M$
Q2 null$295.9M$38.0M$
Q1 null$286.6M$38.2M$
Q4 null$317.0M$-17.7M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$60.33

Target (Median)

$56.00

Target Range

$49.00 - $79.00

2 Strong Buy9 Buy4 Hold0 Sell0 Strong Sell
CitigroupBuy
2026-05-07
Wells FargoOverweight
2026-05-07
Evercore ISI GroupIn Line
2026-05-07
Evercore ISI GroupIn Line
2026-04-06
Wells FargoOverweight
2026-02-06

Trading Activity

Insider Trades

View All
Herr Amy E.director
SellTue May 12
Herr Amy E.director
SellTue May 12
Kelderman Kimdirector, officer: Chief Executive Officer
SellThu May 07
Kelderman Kimdirector, officer: Chief Executive Officer
SellThu May 07
Hippel Jamesofficer: CFO
SellThu May 07

Congress Trades

View All
April DelaneySell
Thu May 07
April DelaneySell
Wed Apr 08

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

1.41

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Peers